First Time Loading...

PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS

Watchlist Manager
PhaseBio Pharmaceuticals Inc Logo
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Watchlist
Price: 0.04 USD 5.26% Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

PHAS Price Targets Summary
PhaseBio Pharmaceuticals Inc

There are no price targets for PHAS.
PHAS Lowest Forecast
Wall Street Target
Not Available
PHAS Average Forecast
Wall Street Target
Not Available
PHAS Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
PhaseBio Pharmaceuticals Inc Competitors:
Price Targets
CIR
Circassia Group PLC
29% Upside
PTCT
PTC Therapeutics Inc
13% Downside
AMGN
Amgen Inc
0% Upside
M
235980
MedPacto Inc
147% Upside
CIR
Circassia Group PLC
29% Upside
PTCT
PTC Therapeutics Inc
13% Downside
AMGN
Amgen Inc
0% Upside
M
235980
MedPacto Inc
147% Upside
CUV
Clinuvel Pharmaceuticals Ltd
81% Upside
MYGN
Myriad Genetics Inc
25% Upside
A
397030
AprilBio Co Ltd
76% Upside
MRNA
Moderna Inc
8% Upside

Revenue
Forecast

Revenue Estimate
PhaseBio Pharmaceuticals Inc

The compound annual growth rate of PhaseBio Pharmaceuticals Inc's revenue for the next 2 years is -35%.

N/A
Past Growth
-35%
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
PhaseBio Pharmaceuticals Inc

Operating Income forecast
is not available for
PhaseBio Pharmaceuticals Inc

Net Income
Forecast

Net Income Estimate
PhaseBio Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
What are analyst estimates?

See Also

Summary
PHAS intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHAS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHAS stock valuation using valuation multiples.
Wall Street Estimates
PHAS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHAS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PHAS's stock price target?
Not Available

PHAS doesn't have any price targets made by Wall Street professionals.

What is PhaseBio Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-35%

The compound annual growth rate of PhaseBio Pharmaceuticals Inc's revenue for the next 2 years is -35%.

ALPHA SPREAD
Join more than 134,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.